Elagolix sodium, estradiol and norethindrone acetate; Elagolix sodium | Abbvie | ||
300 mg, 1mg, and 0.5mg; 300 mg. Capsule, Oral |
Less Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
None | None | ||
None | None | ||
ORIAHNN is a combination of elagolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. | |||
Yes
|
Oriahnn (copackaged) | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 |
---|---|---|---|---|---|---|---|
**** | *** ********* | *** ********* | ******* ***** ******** ************ | ******* ***** ******** ************ | *** ********* | ******* ***** ******** ************ | ******* (***** ******) |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
**** | *** \ ********* | *** **, **** | ******* ***** ******** ************ | **** | ******* *** **** *** *** **** |